Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.

نویسندگان

  • Alain Ravaud
  • Christelle de la Fouchardière
  • Julien Asselineau
  • Jean-Pierre Delord
  • Christine Do Cao
  • Patricia Niccoli
  • Patrice Rodien
  • Marc Klein
  • Bogdan Catargi
چکیده

Disclosures: Alain Ravaud: Consultant/advisory role: Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer Schering; Christelle de la Fouchardière: None; Julien Asselineau: None; Jean-Pierre Delord: None; Christine Do Cao: None; Patricia Niccoli: None; Patrice Rodien: None; Marc Klein: None; Bogdan Catargi: None. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.

Medullary thyroid carcinoma (MTC) accounts for less than 5% of all thyroid carcinomas. Twenty-five percent of MTCs are familial in origin. Among apparently sporadic cases, 7--10% and 40--50% respectively have germinal and somatic mutations in the RET gene.1 Ten-year survival is 65--75%. Surgery is the only curative treatment available. Radiotherapy and chemotherapy have a limited efficacy. A gr...

متن کامل

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.

BACKGROUND We hypothesized that autophagy inhibition would enhance the anticancer efficacy of ret protooncogene-targeted therapy in medullary thyroid cancer. METHODS Medullary thyroid cancer-1.1 and TT cells were treated with sunitinib or sorafenib in the presence or absence of everolimus, trehalose, or small interfering RNA directed against autophagy protein 5. RESULTS Sunitinib and sorafe...

متن کامل

[Use of new molecules in the treatment of advanced thyroid cancer].

s/. 27. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3466--9. 28. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results fro...

متن کامل

Treatment of advanced thyroid cancer refractory to therapy

Radioiodine treatment constitutes the most effective therapeutic option of advanced differentiated thyroid cancer. Unfortunately, about 30% cancers do not show radioiodine uptake or do not respond to therapy. Thyrosine kinase inhibitors (TKI), among them axitinib, cabozantinib, lenvatinib, motesanib, pazopanib, sorafenib, sunitynib and vandetanib, constitute a new group of drugs implemented to ...

متن کامل

Profile of nintedanib in the treatment of solid tumors: the evidence to date

Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or va...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The oncologist

دوره 15 2  شماره 

صفحات  -

تاریخ انتشار 2010